Marco Valgimigli and C. Michael Gibson discuss the PANTHER trial, which compared P2Y12 inhibitor monotherapy with aspririn monotherapy in patients with coronary artery disease.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
